
  
    
      
        Background_NNP
        The_DT Marfan_NNP syndrome_NN (_( MFS_NNP )_) is_VBZ an_DT autosomal_NN dominant_JJ
        connective_JJ tissue_NN disorder_NN with_IN an_DT estimated_VBN incidence_NN of_IN 1_CD
        in_IN 5_CD ,_, 000_CD live_VB births_NNS [_NN 1_CD ]_NN ._. Besides_IN the_DT classic_JJ
        manifestations_NNS in_IN the_DT cardiovascular_JJ ,_, ocular_NN and_CC
        musculoskeletal_NN systems_NNS ,_, frequent_JJ features_NNS include_VBP
        spontaneous_JJ pneumothorax_NN ,_, inguinal_NN herniae_NN ,_, striae_NN
        atrophicae_NN in_IN the_DT skin_NN and_CC lumbosacral_NN dural_NN ectasia_NN ._. There_EX
        is_VBZ pronounced_VBN inter-_NN and_CC intrafamilial_NN variability_NN ._. Age_NNP of_IN
        onset_NN and_CC progression_NN of_IN the_DT various_JJ manifestations_NNS cover_VBP a_DT
        wide_JJ range_NN [_NN 1_CD 2_CD ]_NN ._.
        The_DT MFS_NNP phenotype_NN is_VBZ the_DT result_NN of_IN mutations_NNS in_IN 
        FBN_NNP 1_CD ,_, a_DT large_JJ gene_NN composed_VBN of_IN 65_CD
        exons_NNS encoding_VBG the_DT 350_CD kD_NN fibrillin-_NN 1_CD protein_NN that_WDT is_VBZ the_DT
        major_JJ constituent_NN of_IN microfibrils_NNS in_IN the_DT extracellular_NN
        matrix_NN (_( reviewed_VBN in_IN [_NN 3_CD ]_NN )_) ._. To_TO date_NN ,_, 201_CD unique_JJ 
        FBN_NNP 1_CD mutations_NNS have_VBP been_VBN identified_VBN ,_,
        including_VBG 70_CD (_( 34_CD ._. 8_CD %_NN )_) cysteine_NN substitutions_NNS ,_, 63_CD (_( 31_CD ._. 3_LS %_NN )_)
        other_JJ missense_NN mutations_NNS ,_, 41_CD (_( 20_CD ._. 4_LS %_NN )_) premature_JJ termination_NN
        mutations_NNS ,_, 23_CD (_( 11_CD ._. 4_LS %_NN )_) exon_NN skipping_VBG mutations_NNS ,_, and_CC 4_CD other_JJ
        mutations_NNS ,_, as_IN listed_VBN in_IN the_DT Human_NNP Gene_NNP Mutation_NNP Database_NNP
        (_( HGMD_NNP ,_,
        http_NN :_: /_NN /_NN archive_NN ._. uwcm_NN ._. ac_NN ._. uk_NN /_NN uwcm_NN /_NN mg_NN /_NN search_NN /_NN 127115_CD ._. html_NN )_) [_NN 4_CD ]_NN
        and_CC reported_VBD more_RBR recently_RB [_NN 5_CD ]_NN ._. Although_IN the_DT 
        FBN_NNP 1_CD gene_NN ,_, including_VBG three_CD
        alternatively_RB spliced_JJ 5_CD '_POS untranslated_JJ exons_NNS [_NN 6_CD ]_NN extends_VBZ
        over_IN 235_CD kb_NN of_IN genomic_JJ DNA_NNP in_IN chromosome_NN band_NN 15_CD q_NN 21_CD ._. 1_LS
        http_NN :_: /_NN /_NN genome_NN ._. cse_NN ._. ucsc_NN ._. edu_NN ,_, no_DT major_JJ deletions_NNS have_VBP been_VBN
        identified_VBN except_IN for_IN one_CD report_NN of_IN an_DT exon_NN 60_CD -_: 62_CD genomic_JJ
        deletion_NN [_NN 7_CD ]_NN ._. Some_DT correlations_NNS between_IN 
        FBN_NNP 1_CD mutation_NN genotypes_NNS and_CC
        phenotypes_NNS are_VBP emerging_VBG ._. For_IN example_NN ,_, exon-skipping_JJ
        mutations_NNS in_IN the_DT central_JJ region_NN of_IN the_DT gene_NN ,_, exons_NNS 24_CD -_: 32_CD ,_,
        cause_VBP severe_JJ phenotypes_NNS or_CC neonatal_NN presentations_NNS [_NN 8_CD ]_NN ._.
        But_CC there_EX are_VBP exceptions_NNS ,_, only_RB four_CD of_IN the_DT many_JJ other_JJ
        mutations_NNS in_IN this_DT region_NN cause_NN severe_JJ phenotypes_NNS ,_, while_IN one_CD
        mutation_NN predicted_VBD to_TO lead_VB to_TO skipping_VBG of_IN exon_NN 24_CD was_VBD found_VBN
        in_IN a_DT patient_NN with_IN classic_JJ MFS_NNP [_NN 5_CD ]_NN ._. In_IN contrast_NN ,_, most_JJS
        cysteine_NN substitutions_NNS cause_VBP classic_JJ MFS_NNP with_IN a_DT high_JJ
        frequency_NN of_IN lens_NN dislocation_NN ,_, although_IN some_DT patients_NNS in_IN
        our_PRP$ study_NN did_VBD not_RB meet_VB the_DT Ghent_NNP criteria_NNS for_IN diagnosis_NN of_IN
        MFS_NNP [_NN 9_CD ]_NN ._. Amino-acid_NNP substitutions_NNS not_RB disrupting_VBG
        disulfide_NN bonds_NNS may_MD be_VB associated_VBN with_IN fibrillinopathies_NNS
        other_JJ than_IN MFS_NNP ,_, although_IN mutations_NNS in_IN the_DT calcium-binding_JJ
        consensus_NN sequence_NN have_VBP been_VBN reported_VBN in_IN individuals_NNS with_IN
        classic_JJ MFS_NNP [_NN 5_CD 10_CD 11_CD 12_CD ]_NN ._. It_PRP is_VBZ clear_JJ from_IN the_DT studies_NNS
        reported_VBD so_RB far_RB ,_, that_IN genotype-phenotype_JJ correlations_NNS are_VBP
        not_RB straight-forward_JJ for_IN 
        FBN_NNP 1_CD mutations_NNS ._.
        We_PRP report_VBP here_RB two_CD multi-exon_JJ deletion_NN mutations_NNS of_IN 
        FBN_NNP 1_CD ._. We_PRP located_VBN the_DT deletion_NN
        breakpoints_NNS in_IN introns_NNS and_CC characterized_VBD the_DT mutant_JJ RNA_NNP and_CC
        protein_NN phenotypes_NNS ._. Partial_NNP deletion_NN of_IN an_DT 8_CD -_: cysteine_NN
        (_( LTBP-like_NNP )_) domain_NN and_CC loss_NN of_IN the_DT downstream_JJ 6_CD -_: cysteine_NN
        calcium-binding_JJ (_( cb_NN )_) epidermal_NN growth_NN factor_NN (_( EGF_NNP )_) -_: like_IN
        domain_NN caused_VBD protein_NN instability_NN and_CC classic_JJ MFS_NNP ._. 
        De_NNP novo_NN deletion_NN of_IN three_CD cbEGF-like_JJ
        domains_NNS encoded_JJ by_IN exons_NNS 44_CD -_: 46_CD resulted_VBD in_IN a_DT severe_JJ form_NN of_IN
        MFS_NNP diagnosed_VBD in_IN infancy_NN ._. Both_DT mutations_NNS lead_VBP to_TO the_DT
        synthesis_NN of_IN mutant_JJ FBN_NNP 1_CD proteins_NNS that_WDT interfere_VBP with_IN
        microfibril_NN assembly_NN ,_, resulting_VBG in_IN significantly_RB reduced_VBN
        extracellular_NN matrix_NN microfibrils_NNS ._.
      
      
        Patients_NNS and_CC Methods_NNP
        
          Clinical_NNP histories_NNS
          
            Case_NNP 1_CD
            (_( FB_NNP 774_CD )_) :_: Patient_NNP 1_CD ,_, a_DT female_NN ,_, was_VBD born_VBN to_TO a_DT 36_CD yr_NN
            old_JJ father_NN and_CC was_VBD noted_VBN to_TO have_VB long_JJ fingers_NNS at_IN birth_NN ._.
            A_DT diagnosis_NN of_IN MFS_NNP was_VBD made_VBN at_IN age_NN 15_CD yr_NN ,_, based_VBN on_IN
            bilateral_JJ lens_NN dislocation_NN (_( upward_RB )_) and_CC Marfanoid_NNP
            skeletal_NN features_NNS ._. Diffuse_NNP red_JJ and_CC pink_JJ cutaneous_JJ
            striae_NN started_VBD to_TO appear_VB at_IN age_NN 15_CD ,_, when_WRB obesity_NN
            developed_VBD ,_, and_CC progressed_VBD throughout_IN life_NN ._. As_IN an_DT adult_NN ,_,
            Patient_NNP 1_CD had_VBD a_DT height_NN of_IN 186_CD cm_NN with_IN long_JJ arms_NNS and_CC
            legs_NNS ,_, a_DT narrow_JJ highly_RB arched_JJ palate_NN and_CC dental_JJ
            crowding_VBG ,_, chest_NN asymmetry_NN and_CC pectus_JJ deformity_NN (_( upper_JJ
            sternum_NN protrudes_NNS )_) ,_, hyperextensible_JJ large_JJ and_CC small_JJ
            joints_NNS ,_, arthritis_NN ,_, arachnodactyly_RB ,_, frequent_JJ thumb_NN
            dislocations_NNS ,_, pes_NNS planus_JJ ,_, and_CC thin_JJ ,_, fragile_JJ skin_NN ._.
            Besides_IN ectopia_NN lentis_NNS ,_, ocular_NN features_NNS included_VBD
            high-grade_JJ myopia_NN and_CC glaucoma_NN requiring_VBG surgery_NN at_IN age_NN
            18_CD yr_NN ._. A_DT cardiac_JJ arrhythmia_NN was_VBD treated_VBN with_IN
            beta-blockers_JJ ._. The_DT aortic_JJ root_NN diameter_NN was_VBD 4_CD ._. 5_CD cm_NN by_IN
            echocardiogram_NN at_IN 46_CD yr_NN of_IN age_NN ._. A_DT skin_NN biopsy_NN for_IN
            fibroblast_NN culture_NN was_VBD obtained_VBN at_IN age_NN 40_CD yr_NN ._. There_EX was_VBD
            no_DT family_NN history_NN of_IN MFS_NNP ,_, both_DT parents_NNS were_VBD
            deceased_JJ ._.
          
          
            Case_NNP 2_CD
            (_( FB_NNP 890_CD )_) :_: Born_VBN to_TO a_DT 27_CD yr_NN old_JJ mother_NN and_CC 34_CD yr_NN old_JJ
            father_NN ,_, Patient_NNP 2_CD presented_VBN as_IN a_DT neonate_NN with_IN striking_JJ
            arachnodactyly_RB and_CC pectus_JJ excavatum_NN ._. At_IN 4_CD months_NNS ,_, her_PRP$
            skeletal_NN measurements_NNS were_VBD all_DT above_IN the_DT 97_CD th_NN %_NN ile_NN
            (_( length_NN 66_CD cm_NN ,_, arm_NN span_NN 67_CD cm_NN ,_, middle_JJ finger_NN length_NN 5_CD
            cm_NN ,_, foot_NN length_NN 10_CD cm_NN )_) and_CC the_DT upper-to-lower_JJ segment_NN
            ratio_NN of_IN 1_CD ._. 27_CD was_VBD significantly_RB below_IN normal_JJ for_IN age_NN ._.
            She_PRP had_VBD mild_JJ contractures_NNS of_IN elbows_NNS and_CC knees_NNS ,_, a_DT long_JJ
            face_NN with_IN deep-set_JJ eyes_NNS ,_, bilateral_JJ iridodonesis_NNS and_CC
            high-grade_JJ myopia_NN ._. Bilateral_NNP lens_NN dislocation_NN was_VBD
            confirmed_VBN at_IN age_NN 3_CD yr_NN ._. During_IN early_JJ childhood_NN ,_, she_PRP
            developed_VBD severe_JJ progressive_JJ thoracolumbar_NN scoliosis_NNS
            (_( >_NN 80_CD degrees_NNS )_) requiring_VBG spinal_JJ fusion_NN procedures_NNS ._.
            Episodes_NNP of_IN supraventricular_JJ tachycardia_NN and_CC cardiac_JJ
            arrhythmia_NN were_VBD treated_VBN with_IN cardioversion_NN and_CC
            beta-blockers_JJ ._. Starting_VBG in_IN infancy_NN ,_, her_PRP$ aortic_JJ root_NN
            dilated_JJ rapidly_RB to_TO a_DT diameter_NN of_IN 4_CD ._. 5_CD cm_NN at_IN age_NN 6_CD yr_NN ._.
            She_PRP developed_VBD mitral_NN regurgitation_NN and_CC mitral_NN and_CC
            tricuspid_NN valve_NN prolapse_NN ._. Her_PRP$ joints_NNS became_VBD
            increasingly_RB hypermobile_NN ._. Before_IN valve-replacement_JJ
            surgery_NN ,_, her_PRP$ severe_JJ pectus_JJ excavatum_NN was_VBD repaired_VBN ._.
            Throughout_IN childhood_NN ,_, she_PRP had_VBD underdeveloped_JJ
            musculature_NN and_CC lack_NN of_IN subcutaneous_JJ fat_NN ._. To_TO improve_VB
            her_PRP$ nutritional_JJ status_NN ,_, she_PRP received_VBD nasogastric_JJ tube_NN
            feedings_NNS at_IN night_NN ._. Photos_NNP of_IN Patient_NNP 2_CD were_VBD recently_RB
            published_VBN (_( Figure_NN 13_CD ._. 2_LS a-d_JJ in_IN [_NN 13_CD ]_NN )_) ._. There_EX was_VBD no_DT
            family_NN history_NN of_IN MFS_NNP ._.
          
        
        
          PCR_NNP and_CC direct_JJ sequencing_VBG
          Genomic_NNP DNA_NNP and_CC total_JJ RNA_NNP were_VBD extracted_VBN from_IN
          fibroblast_NN cultures_NNS established_VBN from_IN skin_NN biopsies_NNS as_IN
          described_VBN [_NN 14_CD ]_NN ._. Long-range_NNP RT-PCR_NNP amplification_NN of_IN
          FBN_NNP 1_CD cDNA_NN fragments_NNS and_CC restriction_NN enzyme_NN digestions_NNS
          were_VBD performed_VBN as_RB previously_RB reported_VBD [_NN 8_CD ]_NN ._. Fragments_NNP
          migrating_VBG abnormally_RB in_IN agarose_NN gel_NN electrophoresis_NNS were_VBD
          excised_VBN ,_, purified_JJ with_IN the_DT QIAquick_NNP Gel_NNP Extraction_NNP Kit_NNP
          (_( QIAGEN_NNP )_) and_CC directly_RB sequenced_JJ with_IN fluorescent_NN
          terminators_NNS on_IN an_DT ABI_NNP Prism_NNP 377_CD DNA_NNP sequencer_NN
          (_( Perkin-_NNP Elmer_NNP )_) ._. To_TO define_VB the_DT deletion_NN endpoints_NNS ,_, we_PRP
          amplified_VBN genomic_JJ DNA_NNP with_IN the_DT ExpandTM_NNP PCR_NNP System_NNP
          (_( Boehringer_NNP Mannheim_NNP )_) ._. The_DT thermal_JJ profile_NN for_IN long-range_JJ
          PCR_NNP was_VBD as_IN follows_VBZ :_: denaturation_NN for_IN 2_CD min_NN at_IN 94_CD °_NN C_NNP ,_, then_RB
          35_CD cycles_NNS of_IN denaturation_NN (_( 10_CD s_VBZ at_IN 94_CD °_NN C_NNP )_) ,_, annealing_VBG (_( 30_CD s_VBZ
          at_IN 60_CD °_NN C_NNP )_) ,_, and_CC extension_NN (_( 8_CD min_NN at_IN 68_CD °_NN C_NNP )_) ,_, followed_VBN by_IN a_DT
          final_JJ extension_NN step_NN of_IN 7_CD min_NN at_IN 68_CD °_NN C_NNP ._.
          Primers_NNP used_VBD for_IN genomic_JJ amplifications_NNS and_CC their_PRP$
          location_NN in_IN exons_NNS :_:
          774_CD F_NN ,_, 5_CD '_POS -_: AAGCCCTCTGAACAGTGTCCCATCCCAAGT-_NNP 3_CD '_POS (_( exon_NN
          41_CD )_) ;_:
          774_CD R_NN ,_, 5_CD '_POS -_: TTGCACTGTCCTGTGGAGGTGAAGCGGTAG-_NNP 3_CD '_POS (_( exon_NN
          44_CD )_) ._.
          890_CD F_NN ,_, 5_CD '_POS -_: AGATCCCAGGGGTCTGTGAAAATGGAGTGT-_NNP 3_CD '_POS (_( exon_NN
          43_CD )_) ;_:
          890_CD R_NN ,_, 5_CD '_POS -_: TTGCACTGGCACTGGAAAGACCCCACTGTA-_NNP 3_CD '_POS (_( exon_NN
          47_CD )_)
          We_PRP purified_JJ the_DT genomic_JJ amplicons_NNS with_IN exonuclease_NN and_CC
          shrimp_NN alkaline_NN phosphatase_NN (_( United_NNP States_NNPS Biochemical_NNP )_)
          and_CC sequenced_JJ them_PRP directly_RB with_IN primers_NNS E_NNP 41_CD S_NNP ,_, E_NNP 43_CD S_NNP ,_,
          E_NNP 44_CD AS_NNP and_CC E_NNP 47_CD AS_NNP [_NN 15_CD ]_NN ._.
          To_TO sequence_NN the_DT junction_NN fragments_NNS from_IN both_DT strands_NNS ,_,
          we_PRP performed_VBD PCR_NNP and_CC sequencing_VBG with_IN primers_NNS 774_CD F_NN and_CC
          reverse_VB primer_NN E_NNP 43_CD +_NN 355_CD (_( 5_CD '_POS -_: CAA_NNP AGT_NNP CTC_NNP TGT_NNP CTG_NNP GAA_NNP GAG_NNP
          AAA_NNP TGA_NNP TTT_NNP TGA-_NNP 3_CD '_POS )_) for_IN FB_NNP 774_CD ,_, and_CC with_IN forward_RB primer_NN
          E_NNP 44_CD -_: 343_CD (_( 5_CD '_POS -_: CCT_NNP TAG_NNP CTT_NNP CCC_NNP AAA_NNP GTG_NNP CTA_NNP GGA_NNP TTA-_NNP 3_CD '_POS )_) and_CC
          890_CD R_NN for_IN FB_NNP 890_CD ._.
        
        
          Quantitation_NNP of_IN allele-specific_JJ
          FBN_NNP 1_CD transcripts_NNS
          Patient_NNP 1_CD was_VBD heterozygous_JJ for_IN the_DT 
          Rsa_NNP I_PRP polymorphism_NN in_IN the_DT 3_CD '_POS UTR_NNP ._.
          RT-PCR_NNP and_CC 
          Rsa_NNP I_PRP digestion_NN were_VBD carried_VBN out_IN as_IN
          described_VBN [_NN 16_CD ]_NN ._. The_DT products_NNS of_IN the_DT two_CD alleles_NNS were_VBD
          distinguished_VBN by_IN SSCA_NNP and_CC silver_NN staining_VBG ,_, according_VBG to_TO
          the_DT protocol_NN provided_VBN by_IN the_DT manufacturer_NN (_( Bio_NNP Rad_NNP ,_,
          Hercules_NNP ,_, CA_NNP )_) ,_, and_CC were_VBD subsequently_RB quantified_VBN by_IN
          scanning_VBG densitometry_NN ._.
        
        
          Quantitative_NNP pulse-chase_JJ analysis_NN of_IN fibrillin-_NN 1_CD
          protein_NN
          Primary_JJ fibroblast_NN cultures_NNS from_IN patients_NNS and_CC control_NN
          individuals_NNS were_VBD grown_VBN to_TO confluency_NN and_CC then_RB
          metabolically_RB labeled_VBN with_IN 35_CD S-_NNP cysteine_NN as_IN described_VBN [_NN 17_CD
          18_CD ]_NN ._. The_DT soluble_JJ cell_NN lysis_NNS fraction_NN ,_, containing_VBG newly_RB
          synthesized_JJ labeled_VBN fibrillin-_NN 1_CD molecules_NNS ,_, and_CC the_DT
          insoluble_JJ fraction_NN ,_, representing_VBG the_DT labeled_VBN fibrillin_NN in_IN
          the_DT extracellular_NN matrix_NN ,_, were_VBD fractionated_JJ by_IN SDS_NNP
          polyacrylamide_NN gel_NN electrophoresis_NNS and_CC autoradiographed_JJ ._.
          Labeled_NNP fibrillin-_NN 1_CD was_VBD identified_VBN and_CC quantified_VBN as_IN
          described_VBN [_NN 17_CD 18_CD ]_NN ._. More_RBR recently_RB ,_, the_DT results_NNS were_VBD
          replicated_VBN by_IN use_NN of_IN a_DT phosphorimager_NN ._. The_DT levels_NNS of_IN
          fibrillin-_NN 1_CD production_NN and_CC deposition_NN in_IN the_DT
          extracellular_NN matrix_NN were_VBD expressed_VBN as_IN the_DT percentage_NN of_IN
          values_NNS obtained_VBN for_IN simultaneously_RB studied_VBN normal_JJ control_NN
          fibroblast_NN cultures_NNS ._.
        
      
      
        Results_NNS and_CC Discussion_NNP
        We_PRP developed_VBD a_DT long_JJ RT-PCR_NNP approach_NN to_TO screen_VB for_IN
        exon-skipping_JJ and_CC large_JJ deletion_NN mutations_NNS in_IN the_DT 
        FBN_NNP 1_CD gene_NN ._. PCR_NNP with_IN three_CD sets_NNS of_IN
        primer_NN pairs_NNS amplifies_NNS overlapping_VBG fragments_NNS :_: exons_NNS 1_CD -_: 31_CD
        (_( 3972_CD bp_NN )_) ,_, exons_NNS 29_CD -_: 52_CD (_( 3011_CD bp_NN )_) and_CC exons_NNS 47_CD -_: 65_CD (_( 2971_CD
        bp_NN )_) from_IN skin_NN fibroblast-derived_JJ total_JJ RNA_NNP ._. The_DT amplicons_NNS
        are_VBP digested_VBN with_IN restriction_NN enzymes_NNS that_WDT generate_VBP
        individually_RB recognizable_JJ fragments_NNS with_IN known_VBN sequence_NN
        content_NN ._. A_DT total_NN of_IN 60_CD patients_NNS were_VBD screened_VBD with_IN this_DT
        method_NN ,_, 55_CD of_IN which_WDT met_VBD diagnostic_JJ criteria_NNS for_IN MFS_NNP and_CC 5_CD
        had_VBD partial_JJ manifestations_NNS ._. All_DT of_IN these_DT skin_NN fibroblast_NN
        samples_NNS had_VBD previously_RB been_VBN screened_VBD with_IN a_DT cDNA_NN
        amplification_NN /_NN SSCA_NNP protocol_NN [_NN 14_CD ]_NN and_CC a_DT genomic_JJ DNA_NNP /_NN exon_NN
        amplification_NN method_NN [_NN 15_CD ]_NN with_IN negative_JJ results_NNS ._. As_IN
        reported_VBD previously_RB ,_, the_DT long_JJ RT-PCR_NNP method_NN identified_VBD six_CD
        samples_NNS with_IN transcripts_NNS skipping_VBG exons_NNS 18_CD ,_, 31_CD ,_, 46_CD ,_, 49_CD ,_, 56_CD
        or_CC 58_CD that_WDT were_VBD caused_VBN by_IN nucleotide_NN substitutions_NNS at_IN
        splice_NN sites_NNS [_NN 8_CD ]_NN ._. In_IN another_DT patient_NN ,_, skipping_VBG of_IN exon_NN
        51_CD was_VBD discovered_VBN to_TO be_VB due_JJ to_TO a_DT silent_JJ mutation_NN within_IN the_DT
        exon_NN ,_, possibly_RB affecting_VBG a_DT splicing_VBG enhancer_NN binding_JJ site_NN [_NN
        19_CD ]_NN ._. Here_RB we_PRP report_VBP abnormal_JJ fragments_NNS seen_VBN after_IN 
        Taq_NNP I_PRP digestion_NN of_IN the_DT exon_NN 29_CD -_: 52_CD
        amplicons_NNS (_( Fig_NNP ._. 1_LS a_DT )_) ._. Sequence_NNP analysis_NN of_IN the_DT altered_VBN cDNA_NN
        fragments_NNS revealed_VBD a_DT deletion_NN of_IN exons_NNS 42_CD and_CC 43_CD in_IN patient_NN
        1_CD and_CC a_DT deletion_NN of_IN exons_NNS 44_CD -_: 46_CD in_IN patient_NN 2_CD (_( Fig_NNP ._. 1_LS b_SYM )_) ._.
        In_IN both_DT cases_NNS ,_, we_PRP found_VBD no_DT evidence_NN for_IN sequence_NN
        alterations_NNS ,_, when_WRB we_PRP amplified_VBN the_DT deleted_VBN and_CC flanking_VBG
        exons_NNS and_CC their_PRP$ splice_NN sites_NNS individually_RB from_IN genomic_JJ DNA_NNP
        (_( data_NNS not_RB shown_VBN )_) ._. Therefore_RB ,_, we_PRP suspected_VBD that_IN these_DT normal_JJ
        amplification_NN products_NNS were_VBD derived_VBN from_IN the_DT normal_JJ 
        FBN_NNP 1_CD alleles_NNS ,_, and_CC that_IN the_DT mutant_JJ
        alleles_NNS were_VBD not_RB amplified_VBN by_IN this_DT approach_NN because_IN they_PRP
        carry_VBP gross_JJ genomic_JJ deletions_NNS ._. To_TO test_VB this_DT hypothesis_NNS ,_,
        primer_NN pairs_NNS were_VBD designed_VBN from_IN the_DT flanking_VBG exon_NN sequences_NNS
        for_IN amplification_NN of_IN genomic_JJ DNA_NNP ._. Long-range_NNP PCR_NNP analysis_NN
        revealed_VBD genomic_JJ deletions_NNS ,_, about_IN 5_CD kb_NN in_IN size_NN ,_, in_IN both_DT
        patients_NNS (_( Fig_NNP ._. 2_LS )_) ._. For_IN Case_NNP 1_CD (_( P_NN 1_LS )_) ,_, a_DT 4_CD kb_NN amplicon_NN was_VBD
        obtained_VBN instead_RB of_IN the_DT 9_CD kb_NN amplicon_NN in_IN the_DT normal_JJ control_NN
        sample_NN ._. For_IN Case_NNP 2_CD (_( P_NN 2_LS )_) ,_, a_DT 4_CD ._. 2_CD kb_NN product_NN was_VBD amplified_VBN
        instead_RB of_IN the_DT 9_CD ._. 2_CD kb_NN product_NN in_IN the_DT normal_JJ control_NN ._. In_IN
        both_DT cases_NNS ,_, the_DT PCR_NNP conditions_NNS used_VBN favored_VBD the_DT
        amplification_NN of_IN the_DT shorter_JJR (_( mutant_JJ )_) fragment_NN ,_, although_IN
        the_DT normal_JJ allele_NN was_VBD also_RB present_JJ in_IN the_DT genomic_JJ PCR_NNP
        template_NN (_( Fig_NNP ._. 2_LS )_) ._. Direct_NNP sequencing_VBG of_IN the_DT deletion_NN
        junction_NN amplicons_NNS revealed_VBD the_DT location_NN of_IN the_DT intronic_JJ
        breakpoints_NNS ._. Both_DT deletion_NN events_NNS generated_VBN clean_VB junctions_NNS
        with_IN no_DT missing_VBG or_CC inserted_VBN nucleotides_NNS ._. In_IN Case_NNP 1_CD ,_, the_DT
        breakpoints_NNS are_VBP about_IN 300_CD nt_RB downstream_JJ from_IN exons_NNS 41_CD and_CC
        43_CD ,_, while_IN in_IN Case_NNP 2_CD ,_, they_PRP are_VBP located_VBN about_IN 300_CD nt_RB upstream_RB
        of_IN exons_NNS 44_CD and_CC 47_CD ._. In_IN Case_NNP 1_CD ,_, two_CD sets_NNS of_IN identical_JJ
        pentamers_NNS (_( cagta_NN and_CC ggaaa_NN )_) were_VBD identified_VBN near_IN the_DT
        breakpoints_NNS in_IN introns_NNS 41_CD and_CC 43_CD ._. In_IN Case_NNP 2_CD ,_, the_DT exchange_NN
        occurred_VBD within_IN an_DT identical_JJ pentamer_NN (_( atttt_NN )_) (_( Fig_NNP ._. 2_LS )_) ._.
        None_NN of_IN these_DT sequences_NNS are_VBP known_VBN to_TO predispose_VB to_TO genomic_JJ
        rearrangements_NNS ,_, although_IN short_JJ stretches_NNS of_IN identical_JJ
        sequence_NN are_VBP often_RB found_VBN at_IN the_DT sites_NNS of_IN germline_NN
        translocation_NN and_CC deletion_NN breakpoints_NNS [_NN 20_CD 21_CD 22_CD ]_NN ._.
        Genomic_NNP analysis_NN of_IN the_DT parents_NNS and_CC siblings_NNS of_IN Case_NNP 2_CD
        indicated_VBD that_IN the_DT mutation_NN was_VBD sporadic_JJ ._. Although_IN the_DT
        parents_NNS of_IN Case_NNP 1_CD were_VBD not_RB available_JJ for_IN study_NN ,_, the_DT
        negative_JJ family_NN history_NN suggests_VBZ that_IN this_DT deletion_NN is_VBZ also_RB
        
        de_IN novo_NN ._. Slightly_RB advanced_VBD paternal_NN
        age_NN (_( 36_CD yr_NN and_CC 34_CD yr_NN ,_, respectively_RB )_) may_MD be_VB a_DT factor_NN in_IN both_DT
        cases_NNS ._.
        The_DT effects_NNS of_IN the_DT two_CD deletions_NNS were_VBD studied_VBN at_IN the_DT
        protein_NN level_NN by_IN 35_CD S-_NNP cysteine_NN pulse-chase_JJ analysis_NN ._. Both_DT
        mutant_JJ mRNAs_NNS encode_NN internally_RB deleted_VBN proteins_NNS without_IN a_DT
        frameshift_NN ._. In_IN Case_NNP 2_CD with_IN del_FW exons_NNS 44_CD -_: 46_CD ,_, fibrillin_NN
        synthesis_NN was_VBD normal_JJ (_( 109_CD %_NN of_IN control_NN )_) ,_, indicating_VBG that_IN the_DT
        mutant_JJ fibrillin_NN molecules_NNS are_VBP stable_JJ ._. The_DT mutant_JJ protein_NN
        band_NN ,_, expected_VBN to_TO be_VB 122_CD amino_JJ acids_NNS shorter_JJR ,_, was_VBD not_RB
        resolved_VBN on_IN our_PRP$ gel_NN system_NN ._. The_DT deposition_NN of_IN newly_RB
        synthesized_JJ fibrillin_NN into_IN the_DT matrix_NN was_VBD greatly_RB reduced_VBN
        (_( 13_CD %_NN of_IN normal_JJ )_) ,_, however_RB ,_, suggesting_VBG that_IN the_DT internally_RB
        deleted_VBN mutant_JJ fibrillin-_NN 1_CD molecules_NNS are_VBP secreted_JJ and_CC exert_VB
        a_DT dominant-negative_JJ effect_NN on_IN extracellular_NN microfibril_NN
        assembly_NN ._.
        In_IN Patient_NNP 1_CD ,_, the_DT in-frame_JJ deletion_NN of_IN exons_NNS 42_CD -_: 43_CD
        removed_VBD the_DT C-_NNP terminal_NN 24_CD amino_JJ acids_NNS of_IN the_DT 5_CD thLTBP_NN
        (_( 8_CD -_: cysteine_NN )_) domain_NN and_CC the_DT adjacent_JJ 25_CD thcalcium-binding_JJ
        EGF-like_NNP domain_NN ._. Fibrillin_NNP synthesis_NN levels_NNS were_VBD 55_CD %_NN of_IN
        control_NN and_CC ,_, in_IN addition_NN ,_, matrix_NN deposition_NN was_VBD
        disproportionately_RB reduced_VBN to_TO 16_CD %_NN of_IN control_NN (_( Fig_NNP ._. 3_LS A_DT )_) ._. An_DT
        earlier_JJR independent_JJ study_NN of_IN this_DT patient_NN 's_POS fibroblasts_NNS had_VBD
        revealed_VBN similar_JJ results_NNS :_: 34_CD %_NN for_IN synthesis_NN and_CC 11_CD %_NN for_IN
        deposition_NN (_( T_NN ._. Aoyama_NNP ,_, unpublished_JJ data_NNS )_) ._. To_TO determine_VB
        whether_IN the_DT low_JJ value_NN for_IN synthesis_NN was_VBD due_JJ to_TO reduced_VBN
        mutant_JJ transcript_NN levels_NNS ,_, we_PRP made_VBD use_NN of_IN the_DT 
        Rsa_NNP I_PRP restriction_NN site_NN polymorphism_NN
        in_IN the_DT 
        FBN_NNP 1_CD 3_CD '_POS UTR_NNP for_IN which_WDT the_DT patient_NN is_VBZ
        heterozygous_JJ ._. The_DT SSCA_NNP patterns_NNS of_IN 
        Rsa_NNP I_PRP digested_VBN RT-PCR_NNP products_NNS were_VBD
        indistinguishable_JJ from_IN controls_NNS ,_, indicating_VBG that_IN transcript_NN
        levels_NNS were_VBD equal_JJ for_IN both_DT alleles_NNS (_( Fig_NNP ._. 3_LS B_NNP )_) ._. This_DT leads_VBZ us_PRP
        to_TO conclude_VB that_IN the_DT mutant_JJ mRNA_NN is_VBZ stable_JJ but_CC that_IN the_DT
        mutant_JJ protein_NN ,_, containing_VBG a_DT partially_RB deleted_VBN LTBP-domain_NNP ,_,
        if_IN synthesized_JJ ,_, is_VBZ unstable_JJ and_CC may_MD be_VB processed_VBN to_TO smaller_JJR
        fragments_NNS by_IN proteolytic_JJ cleavage_NN ._. The_DT methods_NNS we_PRP used_VBD did_VBD
        not_RB allow_VB us_PRP to_TO detect_VB such_JJ hypothetical_JJ proteolytic_JJ
        fragments_NNS ._.
        Of_IN more_JJR than_IN 200_CD 
        FBN_NNP 1_CD mutations_NNS reported_VBN ,_, only_RB one_CD is_VBZ
        a_DT multi-exon_JJ deletion_NN [_NN 7_CD ]_NN ._. It_PRP involves_VBZ deletion_NN of_IN exons_NNS
        60_CD -_: 62_CD encoding_VBG three_CD contiguous_JJ cbEGF-like_JJ domains_NNS [_NN 23_CD ]_NN ._.
        This_DT deletion_NN co-segregated_JJ with_IN affected_VBN status_NN in_IN a_DT
        3_CD -_: generation_NN family_NN ._. Skeletal_NNP involvement_NN was_VBD characterized_VBN
        by_IN a_DT moderate_JJ Marfanoid_NNP habitus_JJ with_IN mild_JJ scoliosis_NNS and_CC
        hypermobility_NN of_IN large_JJ and_CC small_JJ joints_NNS ._. Ectopia_NNP lentis_NNS was_VBD
        absent_JJ ._. Retinal_NNP detachment_NN was_VBD reported_VBN in_IN one_CD individual_JJ ._.
        Cardiovascular_NNP features_NNS included_VBD aortic_JJ dilatation_NN in_IN
        mid-life_JJ ,_, one_CD case_NN of_IN dissection_NN at_IN age_NN 56_CD yr_NN ,_, and_CC a_DT high_JJ
        frequency_NN of_IN mitral_NN valve_NN prolapse_NN associated_VBN with_IN
        arrhythmia_NN ._. Immunoprecipitation_NNP studies_NNS with_IN
        fibrillin-specific_JJ antibodies_NNS revealed_VBD the_DT presence_NN of_IN a_DT 15_CD
        kD-smaller_JJ mutant_JJ polypeptide_NN in_IN the_DT medium_NN of_IN
        metabolically_RB labeled_VBN mutant_JJ fibroblasts_NNS [_NN 7_CD ]_NN ._. The_DT
        shortened_VBN molecule_NN was_VBD incorporated_VBN into_IN the_DT extracellular_NN
        matrix_NN and_CC apparently_RB caused_VBN major_JJ disruptions_NNS of_IN
        microfibrils_NNS [_NN 23_CD ]_NN ._.
        Patient_NNP 2_CD described_VBD here_RB also_RB has_VBZ a_DT deletion_NN of_IN three_CD
        contiguous_JJ cbEGF-like_JJ domains_NNS ,_, those_DT encoded_JJ by_IN exons_NNS
        44_CD -_: 46_CD ._. This_DT deletion_NN resulted_VBD in_IN a_DT more_RBR severe_JJ phenotype_NN
        with_IN onset_NN in_IN infancy_NN and_CC a_DT rapidly_RB progressing_VBG clinical_JJ
        course_NN ._. Thus_RB ,_, it_PRP appears_VBZ that_DT deletion_NN of_IN three_CD contiguous_JJ
        EGF-like_NNP domains_NNS can_MD have_VB different_JJ effects_NNS depending_VBG on_IN
        their_PRP$ location_NN within_IN the_DT fibrillin-_NN 1_CD molecule_NN ._. Deletion_NNP of_IN
        the_DT EGF-like_NNP domains_NNS encoded_JJ by_IN exons_NNS 60_CD -_: 62_CD in_IN the_DT
        C-_NNP terminal_NN domain_NN of_IN fibrillin-_NN 1_CD results_NNS in_IN a_DT much_RB less_RBR
        severe_JJ phenotype_NN than_IN deletion_NN of_IN three_CD EGF-like_NNP domains_NNS in_IN
        the_DT second_JJ longest_JJS stretch_NN of_IN EGF-like_NNP domains_NNS (_( between_IN
        exons_NNS 43_CD -_: 49_CD )_) ._. It_PRP has_VBZ been_VBN reported_VBN that_IN 40_CD %_NN of_IN mutations_NNS
        identified_VBN in_IN the_DT region_NN between_IN exons_NNS 59_CD -_: 65_CD ,_, but_CC only_RB 7_CD %_NN
        of_IN mutations_NNS in_IN other_JJ regions_NNS ,_, were_VBD associated_VBN with_IN mild_JJ
        Marfan-like_NNP phenotypes_NNS [_NN 12_CD ]_NN ._. Our_PRP$ results_NNS are_VBP in_IN line_NN
        with_IN the_DT notion_NN of_IN this_DT general_JJ genotype-phenotype_JJ
        correlation_NN ._.
        Deletion_NNP of_IN one_CD EGF-like_NNP domain_NN due_JJ to_TO exon_NN skipping_VBG ,_,
        especially_RB in_IN the_DT region_NN between_IN exon_NN 24_CD and_CC 32_CD ,_, usually_RB
        causes_VBZ severe_JJ neonatal-onset_JJ MFS_NNP [_NN 8_CD 24_CD 25_CD ]_NN ._. Similar_JJ
        deletions_NNS in_IN other_JJ regions_NNS of_IN fibrillin-_NN 1_CD may_MD also_RB result_VB
        in_IN early_JJ onset_NN of_IN cardiovascular_JJ symptoms_NNS [_NN 8_CD ]_NN ._. Patient_NNP
        1_CD ,_, described_VBD here_RB ,_, had_VBD a_DT genomic_JJ deletion_NN of_IN exons_NNS 42_CD and_CC
        43_CD that_IN results_NNS in_IN an_DT in-frame_JJ deletion_NN of_IN part_NN of_IN the_DT 5_CD th_NN
        LTBP-like_NNP domain_NN and_CC the_DT adjacent_JJ downstream_JJ cbEGF-like_JJ
        domain_NN ._. Diagnosed_NNP as_IN a_DT teenager_NN ,_, patient_NN 1_CD had_VBD the_DT skeletal_NN
        and_CC skin_NN findings_NNS of_IN MFS_NNP ,_, bilateral_JJ dislocated_JJ lenses_NNS and_CC ,_,
        at_IN the_DT age_NN of_IN 46_CD yr_NN ,_, a_DT mildly_RB dilated_JJ aortic_JJ root_NN ._. In_IN
        contrast_NN to_TO the_DT cases_NNS with_IN deleted_VBN EGF-like_NNP domains_NNS ,_, her_PRP$
        mutant_JJ protein_NN was_VBD unstable_JJ ._. We_PRP obtained_VBD a_DT similar_JJ result_NN
        in_IN a_DT case_NN of_IN exon_NN 51_CD skipping_VBG due_JJ to_TO a_DT silent_JJ C_NNP >_NN T_NN
        transition_NN at_IN a_DT CpG_NNP dinucleotide_NN [_NN 19_CD ]_NN ._. In-frame_NNP deletion_NN
        of_IN exon_NN 51_CD removes_VBZ 22_CD amino_JJ acids_NNS of_IN the_DT 6_CD thLTBP-like_JJ
        domain_NN ._. In_IN this_DT patient_NN 's_POS fibroblasts_NNS ,_, fibrillin_NN synthesis_NN
        was_VBD 41_CD %_NN of_IN control_NN and_CC deposition_NN was_VBD reduced_VBN to_TO 5_CD %_NN ,_, while_IN
        the_DT mutant_JJ mRNA_NN level_NN was_VBD normal_JJ as_IN shown_VBN here_RB in_IN Fig_NNP ._. 3_LS ._.
        In_IN addition_NN ,_, we_PRP found_VBD that_IN certain_JJ cysteine_NN substitutions_NNS
        in_IN EGF-like_NNP domains_NNS and_CC located_VBN immediately_RB N-_NNP terminal_NN of_IN
        LTBP-like_NNP domains_NNS ,_, cause_VB protein_NN instability_NN and_CC greatly_RB
        reduced_VBN matrix_NN deposition_NN [_NN 9_CD ]_NN ._. Taken_VBN together_RB ,_, our_PRP$ data_NNS
        support_VBP a_DT model_NN in_IN which_WDT misfolding_VBG or_CC partial_JJ deletion_NN of_IN
        LTBP-like_NNP domains_NNS results_NNS in_IN proteolytic_JJ cleavage_NN of_IN the_DT
        mutant_JJ fibrillin_NN molecules_NNS ._. We_PRP hypothesize_NN that_IN truncated_JJ
        intermediates_NNS interfere_VBP with_IN microfibril_NN assembly_NN and_CC ,_,
        thus_RB ,_, produce_VBP the_DT low_JJ levels_NNS of_IN matrix_NN deposition_NN observed_VBD ._.
        This_DT hypothesis_NNS is_VBZ not_RB only_RB based_VBN on_IN analysis_NN of_IN Case_NNP 1_CD
        reported_VBD here_RB but_CC on_IN a_DT similar_JJ analysis_NN of_IN five_CD previously_RB
        reported_VBD cases_NNS ,_, one_CD with_IN exon_NN 51_CD skipping_VBG [_NN 19_CD ]_NN and_CC four_CD
        with_IN cysteine_NN substitutions_NNS immediately_RB N-_NNP terminal_NN of_IN the_DT
        LTBP_NNP like_IN domains_NNS [_NN 9_CD ]_NN ._. It_PRP is_VBZ also_RB possible_JJ ,_, however_RB ,_,
        that_IN proteolytic_JJ fragments_NNS of_IN the_DT mutant_JJ protein_NN associate_JJ
        with_IN the_DT normal_JJ length_NN fibrillin_NN molecules_NNS and_CC inhibit_VB
        their_PRP$ secretion_NN ._. Future_NNP focused_VBD mechanistic_JJ studies_NNS are_VBP
        needed_VBN to_TO test_VB our_PRP$ hypothesis_NNS ._.
        The_DT FBN_NNP 1_CD mutation_NN detection_NN rate_NN for_IN individuals_NNS with_IN
        clinically_RB diagnosed_VBN MFS_NNP is_VBZ currently_RB about_IN 75_CD %_NN when_WRB the_DT
        gene_NN is_VBZ completely_RB screened_VBD with_IN a_DT DNA-based_NNP PCR_NNP
        amplification_NN protocol_NN of_IN individual_JJ exons_NNS [_NN 15_CD 26_CD ]_NN ._.
        Genomic_NNP deletions_NNS such_JJ as_IN the_DT ones_NNS reported_VBD here_RB are_VBP not_RB a_DT
        frequent_JJ cause_NN of_IN human_JJ disease_NN and_CC would_MD be_VB missed_VBN by_IN this_DT
        approach_NN ._. To_TO search_VB for_IN additional_JJ large_JJ genomic_JJ
        rearrangements_NNS ,_, we_PRP carried_VBD out_RP Southern_NNP analyses_NNS of_IN 
        BamH_NNP I_PRP ,_, 
        Sac_NNP I_PRP and_CC 
        Bgl_NNP II_NNP digested_VBN genomic_JJ DNA_NNP from_IN 18_CD
        fibroblasts_NNS strains_NNS that_WDT were_VBD negative_JJ for_IN 
        FBN_NNP 1_CD mutation_NN screening_NN by_IN other_JJ
        methods_NNS ,_, but_CC had_VBD shown_VBN abnormal_JJ fibrillin_NN biosynthetic_JJ
        profiles_NNS by_IN pulse-chase_JJ analysis_NN ._. The_DT blots_NNS were_VBD hybridized_JJ
        successively_RB with_IN the_DT three_CD overlapping_VBG long-range_JJ RT-PCR_NNP
        fragments_NNS covering_VBG the_DT FBN_NNP 1_CD coding_VBG region_NN ,_, that_WDT were_VBD
        generated_VBN from_IN a_DT normal_JJ cDNA_NN template_NN as_IN described_VBN above_IN ._.
        While_IN we_PRP identified_VBD several_JJ restriction_NN fragment_NN length_NN
        polymorphisms_NNS ,_, no_DT evidence_NN for_IN major_JJ deletions_NNS or_CC
        rearrangements_NNS was_VBD found_VBN (_( data_NNS not_RB shown_VBN )_) ._. Thus_RB ,_, we_PRP have_VBP
        only_RB detected_VBN two_CD genomic_JJ deletions_NNS out_IN of_IN 105_CD unique_JJ
        disease-causing_JJ FBN_NNP 1_CD mutations_NNS identified_VBN in_IN our_PRP$
        laboratory_NN ._. The_DT Human_NNP Gene_NNP Mutation_NNP Database_NNP (_( as_IN of_IN
        08_CD /_NN 14_CD /_NN 01_CD )_) contains_VBZ 23_CD ,_, 345_CD unique_JJ mutations_NNS in_IN 1069_NNP genes_NNS ._.
        Of_IN those_DT ,_, 1166_CD (_( 5_CD %_NN )_) are_VBP gross_JJ deletions_NNS
        http_NN :_: /_NN /_NN archive_NN ._. uwcm_NN ._. ac_NN ._. uk_NN /_NN uwcm_NN /_NN mg_NN /_NN hgmd_NN 0_CD ._. html_NN [_NN 27_CD ]_NN
        suggesting_VBG that_IN more_JJR FBN_NNP 1_CD genomic_JJ deletions_NNS await_VBP
        recognition_NN ._. Multi-exon_NNP deletions_NNS are_VBP easily_RB detected_VBN with_IN
        the_DT long_JJ RT-PCR_NNP method_NN we_PRP used_VBD here_RB ,_, that_WDT requires_VBZ RNA_NNP from_IN
        fibroblast_NN cultures_NNS ,_, while_IN Southern_NNP blot_NN analyses_NNS of_IN
        genomic_JJ DNA_NNP are_VBP much_RB more_RBR laborious_JJ and_CC more_RBR difficult_JJ to_TO
        interpret_VB ._. Whereas_IN most_RBS published_VBN genotype-phenotype_JJ
        correlation_NN studies_NNS compare_VBP the_DT nucleotide_NN changes_NNS at_IN the_DT
        DNA_NNP level_NN with_IN the_DT list_NN of_IN phenotypic_JJ features_NNS ,_, we_PRP feel_VBP
        strongly_RB that_IN studies_NNS of_IN the_DT mutant_JJ alleles_NNS at_IN the_DT RNA_NNP and_CC
        protein_NN level_NN are_VBP necessary_JJ to_TO take_VB some_DT of_IN the_DT guesswork_NN
        out_IN of_IN these_DT correlations_NNS ._.
      
      
        Competing_VBG interests_NNS
        None_NN declared_VBD
      
    
  
